Efficacy of clozapine versus standard treatment in adult individuals with intellectual disability and treatment-resistant psychosis (CLOZAID): study protocol of a multicenter randomized clinical trial

Autor: María Alemany-Navarro, Bianca Sánchez-Barbero, Pablo Reguera-Pozuelo, Laura Altea-Manzano, Ana Gómez-Garrido, Idalino Rocha-González, Nathalia Garrido-Torres, Miguel Ruiz-Veguilla, Susana García-Cerro, Clara M. Rosso-Fernández, José María Villagrán-Moreno, Fernando Sarramea, Jorge Cervilla-Ballesteros, Rafael Martínez-Leal, Fermín Mayoral-Cleries, CLOZ-AID Group, Benedicto Crespo-Facorro, Samuel Romero Guillena, Álvaro López Díaz, María Dolores Romero Lemos, María Conde Rivas, Ana Rubio García, Manuel Canal Rivero, Rubén Catalán Barragán, Irene Pans, María Luisa Gutierrez, Eduardo García Ramos-García, Ana Vilches, Beatriz Oda Plasencia, Ramón Terrón, Cristina Valdera, Manuela Rey, Demetrio Mármol, Cristina Esteban, Matilde Castaño, Juan Pedro Alcón, Nicolás Vucinovich, Luis R. Capitán, Cándido García, Matilde Blanco, Álvaro J. Palma, Susana Herrera Caballero, Asunta Torres Laborde, Rocío Torrecilla Olavarrieta, Melquíades Leon Macías, Blanca García Montañes, Juan Luis Prados Ojeda, José Ángel Alcalá Partera, Rafael Manuel Gordillo Urbano, Laura Carrión Expósito, Cristina Gómez Moreno, Pablo Glez Domenech, José Eduardo Muñoz Negro, Ángeles Torres Prieto, Annabel Folch Mas, Juan José Mora Mesa, Rosa Mz Galindo San Valentín, Carlos Peña Salazar, Ana Isabel Domínguez Panchón, Cristina Irirte Iturria, Paula Muñoz Hermoso, David Gil Sanz, Manuel Calvo Muñoz, Georgia Denisa Simon, Elena Rodríguez Cano, Edith Pomarol Clotet

Publikováno v: Frontiers in Psychiatry, Vol 15 (2024)

BackgroundIntellectual disability (ID) affects approximately 1% of the worldwide population and individuals with ID have a higher comorbidity with mental illness, and specifically psychotic disorders. Unfortunately, among individuals with ID, limited

Externí odkaz: https://doaj.org/article/7a76ef2c6ed14a0ebf8c9198de0a15b0